Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Theravance Biopharma To Sell TRELEGY ELLIPTA Royalty Interests To Royalty Pharma for ~$1.1B In Upfront Cash With Over $1.5B In Potential Total Value

Over $1.5 Billion in Potential Total Value, Including Approximately $1.1 Billion in Upfront Cash, up to $250 Million in Sales-Based Milestone Payments and an Estimated NPV
byBenzinga Newsdesk
July 13, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0
  • Over $1.5 Billion in Potential Total Value, Including Approximately $1.1 Billion in Upfront Cash, up to $250 Million in Sales-Based Milestone Payments and an Estimated NPV Approximately $200 Million of Rights to TRELEGY ELLIPTA Outer Year Royalties1
  • Royalty Pharma to Invest up to $40 Million to Advance Development of Ampreloxetine in Multiple System Atrophy (MSA) in Exchange for Unsecured Low Single-Digit Royalties
  • Theravance Biopharma to Hold a Conference Call Today at 5 pm ET / 2 pm PT / 10 pm IST
 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts